You heard it here! Ambition finally completed and now Gilead can sell Letairis to UT, a real PAH company. Single tablet regimen on the horizon with Adcirca and Letairis. Bye bye!
Adcirca belongs to Lilly marketed by LungRx not UT owned by same parent. Confused? Good. Europe will have single tablet. Lilly won't play here in the US. No sale.
Why would any company buy a drug with only a few years left? Why would Gilead sell a drug that keeps going up in sales year after year? Opsumit sucks, so I see no change. This thread is BS.
